vismodegib · Genentech · NDA 203388
Erivedge
Earliest generic entry, as listed
15 Dec 2028
Blocked by patent: US 9278961. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9278961 | use U-1825 | 15 Dec 2028 |
| US 7888364 | substance, product | 11 Nov 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203388 · 001 · RLD | capsule, oral | 150MG | 15 Dec 2028 |